Drug profile · INN
tislelizumab
TEVIMBRA
tislelizumab (TEVIMBRA) is a programmed cell death protein 1 inhibitor. Associated with BEONE MEDICINES AUS PTY LTD.
Drug details — tislelizumab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 2
- Programs
- 69
- Data quality
- 0.89
Quick answer
tislelizumab (TEVIMBRA) is a programmed cell death protein 1 inhibitor. Associated with BEONE MEDICINES AUS PTY LTD.
Key facts
Mechanism of action
Programmed cell death protein 1 inhibitor
Primary target: Programmed cell death protein 1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study
Structured plan for ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study
NMPA Approval Lung Cancer Immunotherapy: PD-1/PD-L1 Combo Trends 2025
This article delves into the NMPA's approval landscape for lung cancer immunotherapy, highlighting the emerging trends of PD-1/PD-L1 combination therapies by 2025.
FDA Approves Tislelizumab (Tevimbra) for First-Line Advanced Esophageal Cancer
FDA approves Tislelizumab with chemotherapy for first-line advanced esophageal squamous cell carcinoma (ESCC), targeting PD-L1 positive tumors.
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is tislelizumab?
tislelizumab (TEVIMBRA) is a programmed cell death protein 1 inhibitor. Associated with BEONE MEDICINES AUS PTY LTD.
What is the brand name for tislelizumab?
TEVIMBRA is a marketed brand name for tislelizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.